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1. Introduction  
1.1 Background (Schmid, Schmetzer) 
Highly specialized and sensitive defence against infections as well as tumors is provided in 
great part by the adaptive, T-cell-mediated part of our immune system. Those T-cell 
specialists arise out of a cell pool of 25-100 million distinct naïve T-cell clones, after a very 
efficient priming phase by dendritic cells (DC), that present antigens in the context of major 
histocompatibility complexes (MHC), T-cell receptors (TCR) and costimulatory signals. It is 
well known, that T-cells are most important  effectors of cellular tumor immunity and carry 
long lasting  memory. Therefore recent tumor research has focused on the development and 
improvement of T-cell based immunotherapies (Barrett & Le Blanc, 2010; Smits et al., 2011). 
The T-lymphocyte pool includes naïve (Tnaive), effector (Teff), effector memory (Tem) and 
central memory (Tcm), either CD8 or CD4 T-cells. After an antigen driven TCR engagement 
Tnaive proliferate and give rise to large numbers of Teff. Most of them die after depleting 
target cells. Some ‘memory T-cells’ of either Tcm or Tem phenotype remain, persist and can 
differentiate to Teff after a re-challenge with antigens. It has been demonstrated that memory 
T-cells are able to self-renewal and differentiation (Sallusto et al., 2005). However antitumor 
immunity is limited by regulatory T-cells (Treg) that are in general responsible for the 
prevention of autoimmunity, regulation of inflammatory antimicrobial or antitumor 
reactions and are regarded as the mediators of tolerance (Vignali et al., 2008). Treg reactions 
can be either mediated by inhibitory cytokines (IL-10, IL-35, TGF-ß), Granzyme A/B 
dependent cytolysis, CD25 dependent IL-2 deprivation-mediated apoptosis, adenosine 
receptor mediated immunosuppression of  DCs’ maturation (Vignali et al., 2008). Treg 
subtypes can be identified by their expression profiles and be subdivided in resting or 
activated Tregs of either CD4 or CD8 subtype (Miyora et al., 2009; Jordanova et al., 2008; 
Schick et al., 2011). Resting Tregs can convert to activated Tregs after proliferation. The 
functional repertoire of T-cells depends on their survival and their cooperation via cellular 
contact and the secretion of humoral factors. Improved knowledge of these properties 
should contribute to detect or select T-cells with defined markers or functional profiles for 
adoptive therapy. 
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In the past the potential of adoptively transferred T-cells to eradicate tumor cells has been 
intensively studied in patients with melanoma, EBV-associated tumors and especially in 
the context of a transplantation of allogeneic hematopoietic stem cells including 
immunocompetent cells in patients with lymphoid- or myeloid-derived malignant 
diseases (Kahl et al., 2007; Kolb et al., 2004; Schmid et al., 2011; Parmar et al., 2011; 
Moosmann et al., 2010). 
In patients with acute myeloid leukemia (AML), a malignant clonal disease of the 
hematopoietic stem cells, conventional chemotherapy induces remission in 60- 80% of 
patients. However, relapse occurs in the majority of patients in the following two years 
(Buechner et al., 2003). Allogeneic stem cell transplantation (SCT) is considered as a curative 
therapy for patients with AML: Following engraftment of donor cells, the established 
hematopoietic chimerism persists even after discontinuation of immunsuppressive therapy, 
reflecting tolerance both in Graft-versus-Host and Host-versus-Graft direction (Kolb et al., 
2004; Schmid et al., 2011). T-cells of the healthy donor mediate the ‘graft versus leukemia’ 
(GvL), effect which was perceived in principle as early as in the 1960ies. Clinical evidence 
for the efficacy of GvL reactions in AML came from the observation, that  leukemia relapse 
after allogeneic SCT, the most frequent reason of treatment failure in AML, occurred most 
frequently in patients who had either been transplanted from a syngeneic twin, or had 
received a graft which had been depleted from donor T-cells prior to transfusion. In 
contrast, relapse incidence was lowest in patients developing acute or chronic Graft-versus-
Host Disease (GvHD), which represents the second clinical manifestation of the allogeneic 
immune reaction mediated by donor T-cells (Hemmati et al., 2011; Schmid et al., 2007; 
Schmid et al., 2011;  van den Brink et al., 2010). Based on these observations, the infusion of 
donor lymphocytes (DLI) was developed as a form of immunotherapy for relapsed disease 
after allogeneic SCT. However, up to now, not every patient, in particular those with rapidly 
proliferating AML, responds to or permanently benefits from those T-cell based 
immunotherapy.  
1.2 Aims (Schmetzer) 
The ability of T-cells to eliminate tumor cells and even to cure tumors has been 
demonstrated in experimental animal models. In man the development of effective T-cell 
therapies to treat human tumors remains still a challenge. Tumor antigens that elicit curative 
responses have been identified in animal models; in man tumor associated antigens are also 
known, but their use is limited due to HLA-restriction and limited duration of responses. 
This applies also to hematological malignancies as AML. In the last years several 
approaches have been made to further characterize T-cells and to explore the role of soluble 
and cellular factors on the regulation and mediation of antitumor reactions in AML-patients. 
Known tumor antigens may help to identify specific T-cells and their subtypes. This could 
be monitored in the course of treatment and they could be prepared for further treatment. 
However the majority of potential tumor antigens is unknown. Their presence may be 
deduced from T-cell reactions initiated and mediated by leukemia-derived dendritic cells 
(DC), presenting the whole antigenic repertoire of the leukemic cell. In analogy to T-cell 
reactions against known tumor antigens DC-stimulated T-cells reacting against unknown 
tumor antigens may be analysed against healthy cells before further use. In addition the 
identification of possible immune escape phenomena in cases without successful SCT or DLI 
or without antileukemic functions ex vivo could contribute to develop strategies to overcome 
those immunological barriers.  
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In this chapter we want to present experimental and clinical results of our group with a 
special focus on the following topics and discuss perspectives for future therapies: 
 T-cells addressing known (leukemia-) specific antigens 
 T-cells addressing unknown leukemia-specific antigens 
 T-cell profiles to predict antileukemic reactions and prognosis 
 Clinical use of donor T-cells for prevention and treatment of AML relapse after 
allogeneic SCT 
 Perspectives for future therapies: adoptive transfer or in vivo activation of antileukemic 
T-cells? 
2. Research methods (Schmetzer) 
Cellular characterizations (especially of T-cells, leukemic blasts and dendritic cells) were 
performed by Flow Cytometric Analyses applying a panel of marker-specific, fluorochrome 
labelled monoclonal antibodies: T-cells: Naïve T-cells (Tnaive) CD45RO-CCR7+; non-naïve T-
cells (Tnon-naïve) CD45RO+; central memory T-cells (Tcm) CD45RO+CCR7+CD8+; Effector 
memory T-cells (Tem) CD45RO+CCR7-CD27+; Effector T-cells (Teff) CD45RO+CCR7-CD27-; 
Regulatory T-cells (CD8+Treg) CD8+CD25+CD127low; (CD4+Treg) CD4+CD25+CD127low; (Tnaive 
reg) CD25+CD127lowCCR7+CD45RO-; (Tcm reg) CD25+CD127lowCCR7+CD45RO+; (Teff/em reg) 
CD25+CD127lowCCR7-CD45RO+ (Liepert et al., 2010; Vogt  et al., 2011; Schick et al., 2011). 
Blasts: Myeloid cells co-expressing patient-specific markers (e.g. CD34, CD117, CD56, 
CD65); DC: DC co-expressing DC-antigens; Mature DC: DC coexpressing CD83; DCleu: DC 
coexpressing DC-antigens (e.g. CD80, CD86, CD40) with blast-markers; (Schmetzer et al., 
2007; Kremser et al., 2010). Untouched or touched CD4+, CD8+ or CD3+ T-cells were isolated 
by Magnetic labelled cell sorting (MACS) (Schick et al., 2011; Vogt et al., 2011; Grabrucker et 
al., 2010), leukemia-antigen specific T-cells by Interferon gamma (IFN-Ǆ) capture assay 
(Neudorfer et al., 2007) or by MHC-multimer  (Streptamers) staining for several described 
leukemia associated antigens  (Knabel et al., 2002). In some cases spectratyping analyses were 
performed to observe clonal restriction among T-cells characterized by defined T-cell receptor- 
Vß chains (Schuster et al., 2008). The expression of leukemia-associated antigens (LAA; e.g. 
WT1, PRAME, PR1) was evaluated by PCR-technology (Steger et al., 2011). ‘Taq man low 
density arrays’ were used to study expressions of most of the known protein-coding Y-
chromosome genes (Liu et al., 2005). To predict the HLA-A0201 binding potential of selected 
peptides a HLA-A0201 peptide binding assay was performed by using the HLA-A0201 
positive TAP-deficient T2 cell line system (Nijman et al., 1993; Saller et al., 1985). Leukemic 
blasts were cultured in ‘DC-media’ containing a cocktail of immune-modulators and 
cytokines, (thereby converting blasts to leukemia-derived DC (DCleu), theoretically presenting 
the whole leukemic antigen spectrum (Kremser et al., 2010; Schmetzer et al., 2007).  
Alternatively LAA/HA1 or ‘male specific’ antigens were loaded as peptides or full length 
proteins on either unmanipulated or irradiated antigen presenting cells (APC; e.g. MNCs or 
CD4 cell depleted cell fraction (Adhikary et al., 2008),  EBV-transformed B-cells ‘mini-LCL’ 
or DC (Moosmann et al., 2002) were irradiated with 45/80 Gray and used for T-cell 
stimulations as given in figure 3.1.3-1 ( Steger et al., 2012; Bund et al., 2011). Antileukemic 
reactivity of T-effector cells was measured by chromium release-, IFN-Ǆ ELISPOT assays or 
non-radioactive Fluorolysis assays (Bund et al., 2011; Kremser et al., 2010). Intracellular 
cytokine staining (ICS) and cytokine release profiles were performed by FACS (Cytometric 
Bead arrays (CBA)), ELISA or ELISPOT (Elbaz & Shaltout 2001; Schmittel 2000;  Fischbacher 
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et al., 2011; Merle et al., 2011; Bund et al., 2011). In a dog model we performed in addition an 
in vivo immunisation with antigen positive cells (Bund et al., 2011). 
Using these methods we could evaluate antigen expression profiles on T-cells, antigen 
presenting cells or blast cells as well as cytokine secretion profiles assigning these profiles to 
cellular subtypes and correlate them with antileukemic reaction profiles or the clinical 
response to immunotherapies. Moreover we could contribute and quantify reaction profiles 
of ‘antigen stimulated’ or ‘-unstimulated’ as well as of (specifically) selected, enriched or 
cloned T-cells against blast targets. Statistical evaluations were performed with standard 
excel programmes or SPSS software.  
3. Experimental key results 
In the following chapter the most important experimental  results generated by our group 
are summarized. Responsible co-workers and cooperation partners are given and their 
contributions listed below. 
3.1 T-cells addressing known (leukemia-) specific antigens  
3.1.1 Y-chromosome encoded proteins overexpressed in acute myeloid leukemia and 
CD8+ T-cell reactions (Groupleaders: Kolb, Adamski; Scientists: Bund, Gallo)  
In haploidentical SCT we and others observed that female-donors (especially mothers) show 
a higher GvL reactivity against male-patients (particularly sons) compared to all other 
haploidentical donor-recipient combinations for AML patients (Stern et al., 2008). These 
effects could be due to Y-chromosome-encoded male minor histocompatibility antigens 
(minor-H-Ags, mHAs) recognized by female alloimmune effector (memory) T-cells, 
immunized during pregnancy, in the context of a GvL-reaction (Ofran et al., 2010). We 
studied the expression profiles of Y-chromosome genes in healthy male stem cell donors 
compared to male AML patients in order to possibly detect new AML-typical Y-restricted 
expression patterns. Blasts from male patients with acute (myelo) monocytic leukemia and 
monocytes from healthy male donors as the healthy control counterpart were used to 
determine and compare the expression profiles of Y-chromosome genes. We could detect 
several genes being up-regulated in male AML-cells. Among those, we focused on PCDH11, 
VCY, TGIF2LY, known to be expressed only in male tissues and its X-chromosome-encoded 
homolog TGIF2LX (Blanco-Arias et al., 2002; Skaletsky et al., 2003; Gallo et al., 2011). In a 
next step, we studied the immunological impact of the identified Y-encoded genes. We 
analyzed the proteins encoded by those four genes for the presence of nonameric peptides 
that could potentially bind HLA-A0201 molecules. Such analysis was performed with the 
help of publicly available peptide-motif scoring systems (http://bimas.dcrt.nih.gov/molbio/ 
hla_bind/ and http://www.syfpeithi.de; Rammensee et al., 1995). High-scoring peptides were 
not found for PCDH11, whereas HLA-A0201-binding peptides could be identified in silico 
for the VCY, TGIF2LY and TGIF2LX genes. Their effective binding efficacy was determined 
in a standard HLA-A0201-T2 binding assay: Two peptides derived from VCY as well as 
from TGIF2LX and one derived from TGIF2LY were able to bind to the HLA-A0201-
molecules of the T2 cells. Furthermore these peptides were tested for their ability to induce a 
CD8+ T-cell response: we selected CD3+ T-cells from female volunteers and cultured them 
in the presence of T2 cells loaded with the different Y-chromosome-encoded peptides for 
four weeks. We could show that the VCY-encoded peptide G54 stimulated female effector T-
cells as shown by a specific lysis of G54-loaded T2 target cells in a chromium release assay 
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(Figure 3.1.1-1). Further research will focus on the immunogenic G54-peptid particularly 
with respect to our assumption that mothers (who had given birth to a son) bear CD8+ T-
cells being reactive to male-specific antigens, leading to a strong GvL effect. Moreover, 
peptides restricted to other HLA-types will also be investigated. 
In conclusion we identified three new potentially antileukemic, male-specific human genes 
being upregulated in blasts of male AML-patients. These might be valuable targets for T-cells.  
As a rule Y-chromosome coded antigens are expressed in all cells of the organism. However 
some data have been reported, that differentially spliced forms of the Y-linked UTY 
(ubiquitously-transcribed tetratricopeptide-repeat-gene, Skaletsky et al., 2003) may be 
restricted in a tissue restricted fashion (Warren et al., 2000). UTY is highly conserved in man 
and animal species. We worked out in a dog model in vitro and in vivo that the Y-
chromosome coded mHA UTY might be a promising candidate target-structure to improve 
GvL immune reactions after SCT: female T-cells were stimulated with either autologous 
(female) DCs, loaded with three different UTY-derived (male) peptides or with allogeneic, 
donor-matched male cells (PBMCs) endogenously expressing UTY. We identified 3 out of 15 
identified UTY-encoded peptides bearing immunological potential to stimulate ‘antimale’-
(i.e. anti-UTY-) directed immune reactions. Amongst those, W248 showed highest 
immunogenic potential in both in vitro and in vivo settings: In vitro expanded CTLs 
specifically recognized mainly bone-marrow (BM) from DLA-identical male littermates in 
an MHC-I-restricted manner (Figure 3.1.1-2; in vitro). In vivo, comparable W248-(UTY-) 
specific reactivity against BM was also obtained after stimulation and immunization of a 
female dog with DLA-identical male PBMCs (Table 3.1.1-1; in vivo (Bund et al., 2001)).  
 
 
T2-cells were loaded with the VCY-derived G54-peptide and incubated with female HLA-A0201+ T-cells 
for 4 weeks. Cytotoxic activity of the generated G54-specific CTLs were tested in Chromium release assays 
(E:T = 8.75:1 to 50:1). T-cells specifically lysed T2-cells loaded with the cognate peptides G54 (G54, ● red). 
T2-cells alone (T20, ○), T2-cells loaded with I540S (non-HLA-A0201 binding; HFLLWKLIA; T2+I540S, ▲) 
and K562-cells (NK-cell target, ×) were not recognized or only to a low extent 
Fig. 3.1.1-1. Female T-cells stimulated with the Y-chromosomally encoded G54-peptid can 
specifically lyse T2-cells loaded with G54 in vitro.  
www.intechopen.com
 
New Advances in Stem Cell Transplantation 
 
64
 E:T* 
male 
DLA-identical 
target cells 
W248-specific 
spots/100,000 T-cells* 
In vitro 80:1 
BM 85 
BM + <anti MHC-I antibody> 24 
In vivo 20:1 
BM 45 
BM +  <anti MHC-I antibody> 25 
BM + W248-peptide 35 
BM + W248-peptide + 
<anti MHC-I antibody> 
15 
BM bone marrow; <MHC-I>=<MHC-I>-antibody. 
* E:T= Effector-to-target-ratio 
**number of UTY-specific spots per 100,000 T-cells 
T-cells from female dog(s) were expanded using autologous DCs pulsed with the UTY-encoded peptide 
W248 (in vitro; n=3/6) or male DLA-identical PBMCs (in vivo; n=1). Female UTY-specific T-cell 
recognition was determined in IFN-Ǆ-ELISPOT-assays (day 21-28 (E:T = 80:1) and day 49 (E:T = 20:1), 
respectively). Female T-cells mainly recognized male DLA-identical BM in vitro and in vivo verifying the 
male-specific UTY-presentation. T-cells` MHC-I-restriction was shown by an anti-MHC-class-I-mAb. 
Table 3.1.1-1 Female dog T-cells stimulated with UTY (W248)-peptides loaded on 
autologous DC in vitro or male DLA-identical PBMC in vivo specifically recognized  ‘male’ 
target cells 
Taken together we could demonstrate, that female dog effector T-cells could be specifically 
stimulated against male, UTY-gene product specific cells meaning in turns, that UTY seems 
to be a promising candidate antigen to improve GvL reactions after SCT.  
3.1.2 LAA-specific CD8+ T-cells (Groupleaders: Busch, Borkhardt, Kolb; scientists: 
Doessinger, Steger, Schuster) 
Between 60-90% of AML cases overexpress leukemia-associated antigens (LAA), that means 
antigens that are absent or only weakly expressed in normal tissues (e.g. WT1, PR1 or 
PRAME (Greiner et al., 2006; Steger et al., 2011)). Therefore T-cell based immunotherapeutic 
strategies addressing those LAA-expressing cells could be promising. Alternatively mHAs, 
preferentially expressed on hematopoietic cells, could qualify as T-cell targets in a GvL 
reaction (Mutis & Goulmy, 2002). Principally T-cell based strategies could be based on a 
vaccination with LAA/mHAs or by identification, selection and transfer of LAA/mHAs 
specific T-cells already present in the donor. LAA/mHAs specific T-cells can be found at a 
low frequency in normal persons implying a low level of immunity. Vice versa a long 
lasting immunity against leukemic cells overexpressing LAA or mHAs should imply the 
presence of specific T-cells. Therefore our experimental approach was to detect LAA-specific 
T-cells by MHC-multimer technology in AML patients after SCT. We constructed human 
HLA-A2 peptide multimers (Knabel et al., 2002) and tested CD8+ T-cells in 5 AML- and 2 
MDS-patients after SCT for antigen specificity, as given in table 3.1.2-1 
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Patients (pt) Dgn. 
stage of  
the 
disease at 
T-cell 
aquisition
Cytogen. 
Marker 
at 
first 
dgn.
Blasts 
in PB at 
sample 
aquisi-
tion
IC blast 
phenotype 
(CD) in 
acute 
phases
IC 
mono-
cytes 
(%) 
IC 
B-
cells
(%) 
IC 
T-
cells
(%) 
IC 
NK-
cells 
(%) 
performed 
analyses 
pt 1147 AML-M2 
CR2 after 
SCT and 
DLI
+21,+21
, 
+21
0 7,33,34,117 nd nd nd nd 
MHC-
multimer 
staining 
pt 1148 AML-M2 
CR after 
3rd SCT 
inv 
(3qq) 
0 
13,33,34,11
7 
nd nd nd nd 
MHC-
multimer 
staining, 
ICS 
pt 1149 AML-M4 
CR after 
SCT and 
DLI 
46, XX 0 
13,15,33,34
, 
117 
7 6 14 6 
MHC-
multimer 
staining, 
ICS 
pt 1150 
MDS-
RAEB I 
CR after 
SCT and 
DLI 
-5, +1 
(at 
relapse)
0 
13,33,34,11
7 
11 6 13 7 
MHC-
multimer 
staining, 
ICS 
pt 1151 AML-M4 
CR after 
SCT 
46, XX 5 
15,33,7,65,
64,4 
nd nd 28 12 
MHC-
multimer 
staining, 
ICS 
pt 1152 AML-M5 
CR after 
SCT 
46, XX 0 nd nd nd nd nd 
MHC-
multimer 
staining, 
Spectraty-
ping 
pt 1153 
MDS-
CMML 
Pers after 
SCT and 
DLI 
46, XX 8 nd nd nd nd nd 
MHC-
multimer 
staining, 
ICS, LAA, 
CD4+ exp. 
pt 1154 
MDS-
RAEB II 
CR after 
SCT and 
DLI
46, XY 0 nd 10 3 34 8 
ICS, LAA, 
CD4+  exp. 
pt 1155 
MPS-atyp. 
CML 
CR after 
SCT and 
DLI
t (8;22) 0 nd nd nd nd nd 
ICS, LAA, 
CD4+  exp. 
nd not done; CR complete remission; Rel. relapse; MDS myelodysplastic syndrome; RAEB Refractory 
Anaemia with Excess Blasts; AML-M3 acute myeloid leukemia FAB M2; CMML Chronic 
Myelomonocytic Leukemia; LAA leukemia associated antigen, overexpression analyses compared to 
healthy controls, detected by the RQ= 2-ΔΔct method in MNCs; dgn. diagnosis; ICS intracellular staining; 
CD4+ exp. CD4+ experiments 
Table 3.1.2-1 Patients’characteristics I:  
In all of these 7 cases we could detect LAA-specific CD8+ T-cells (that means more than 
0.1% T-cells with LAA specificity) –although not directed against all given LAA, suggesting 
the persistence of T-cells with antileukemic potential (table 3.1.2-1 and fig 3.1.2-2). Four of 
five cases with two different types of LAA- specific CD8+ T-cells (pt 1149, 1151, 1152, 1153) 
were characterized by long-lasting clinical remissions for more than 2 years. One patient 
with two different types of LAA-specific CD8+ T-cells relapsed after 9 months (pt 1151) and 
in addition the patient with only one type of LAA-specific T-cells, who relapsed after one 
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year (pt 1147). One patient could not be analysed under a clinical point of view since he died 
one month after sample acquisition of an infect (pt 1148, table 3.1.2-2, Steger et al., 2012). 
 
Patients (pt) 
LAA over-
expression 
in MNCs 
(at sample 
preparation)
Peak response 
MHC-Multimer 
staining (% of 
specific CD8+ T- 
cells) 
Cytokine profile 
(IFN-γ, IL-2) after 
LAA-stimulation 
Time to relapse or 
last follow up 
CD 4+/C8+ T-cells  
pt 1147 nd 
A2/WT1 0.11 
A2/PR1 0.13  
A2/PRAME 0.034 
NR/NR 
04/07 local rel.; 
08/09  systemic 
rel., 05/11 CR after 
2nd SCT, DLI and 
3th rel. 
pt 1148 nd 
A2/WT1 0.37
A2/PR1 0.4 
A2/PRAME nd
NR/NR 
03/06 death with 
infect in CR after 
SCT
pt 1149 nd 
A2/WT1 0.61
A2/PR1 0.39 
A2/PRAME 0.4
NR/NR 
until 02/11 in CR 
after SCT 
pt 1150 nd 
A2/WT1 0.27
A2/PR1 0.13 
A2/PRAME 0.081 
NR/NR 
until 03/11 in CR 
after SCT 
pt 1151 nd 
A2/WT1 0.16 
A2/PR1 0.088 
A2/PRAME 0.42 
NR/NR 
11/06 rel; 04/07 
death  after  3th 
DLI, rel. and 2nd 
SCT  
pt 1152* nd 
A2/WT1 0.16
A2/PR1 0.074 
A2/PRAME 0.38 
NR/NR 
until 04/11 in CR 
after SCT 
pt 1153 
WT1 (-),
PRAME 
(+), 
PR1 (-) 
A2/WT1 0.1 
A2/PR1 0.14 
A2/PRAME 0.13 
PRAME 0.32/NR  
until 02/11 in CR 
after SCT 
pt 1154 
WT1 (-),
PRAME (-),
PR1 (-) 
nd NR/NR 
until 07/11 in CR 
after SCT 
pt 1155 
WT1 (-),
PRAME (-),
PR1 (-) 
nd NR/NR 
until 07/11 in CR 
after SCT 
No LAA overexpression (-), 1–10x LAA overexpression (+), compared to healthy controls, analysed by 
the RQ= 2-ΔΔct method; nd not done  
Bold: > 0.1% CD8+ T-cells defined as ‘LAA-specific T-cells present’; * restricted T-cells by spectratyping 
in PRAME- MHC multimer selected T-cells detectable 
Table 3.1.2-2 Anti-LAA-peptide reactive T-cells are detectable by MHC-Multimer staining in 
all given PB samples from AML/MDS patients after allogeneic SCT 
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In one case (pt 1152) we performed spectratyping in T-cells selected for PRAME-specificity 
and could demonstrate a highly restricted TCR-repertoire. This points to a specific clonal 
expansion of CD8+ cells after (in vivo) PRAME challenge by residual PRAME overexpressing 
blasts (Figure 3.1.2-1).  
 
 
 
a) representative FACS-plot shows MHC-Multimer staining from peripheral blood of an AML-patient 
after SCT. 
b) LAA-specific T-cells from PBMCs from AML-pts after SCT were labelled with MHC multimers 
binding T-cells, that recognize frequently overexpressed LAA antigens. PBMCs were analyzed by 
FACS. Healthy donors served as controls and multimer-staining revealed a threshold value of 0.11% 
multimer-positive cells in the CD8 cell fraction.  
c) MHC-multimer positive CD8+ T-cells from peripheral blood of an AML-patient after SCT were 
enriched by FACS sorting. RNA was extracted and Spectratyping of the Vǃ-composition reveals strong 
clonal restriction among TCR-species (1rd row: Vß3-Jß1.5; 2nd row: Vß3-Jß2.1; 3rd row: Vß3-Jß2.5) 
 
Fig. 3.1.2-1. LAA-specific T-cells can be isolated from AML-patients after SCT by MHC 
multimer technique. Selected T-cells are highly Vß restricted 
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Upon in vitro peptide-challenge we could not detect secretion of IFN-Ǆ or IL-2 in T-cells by 
intracellular cytokine staining in 7 out of 8 patients tested (table 3.1.2-2). This however does 
not exclude a cytokine-independent functionality of multimer positive T-cells. Interestingly 
we could detect an IFN-Ǆ response in CD4+ T-cells in one case (pt 1153) with PRAME 
overexpressing leukemic blasts detectable during persisting relapse after SCT. This is very 
surprising as the peptide triggering this response is MHC class I restricted and could 
indicate a CD8 coreceptor independent binding of a MHC I directed TCR and an unusual 
involvement of CD4+ T-cells in the leukemia directed immune response.  
In summary that means, that in general LAA-specific, HLA-A2-restricted CD8+ T-cells can 
be prepared by MHC multimer technology from most of the patients after SCT at various 
time points. Possibly the simultaneous detection of two different LAA-specific CD8+ T-cells 
correlates with a higher chance of longlasting remissions. Optimal time points have to be 
evaluated for the preparation of (sufficient) LAA-specific CD8+ T-cells that could be used 
for adoptive transfer and concerning minimal amounts needed for maintenance of 
remission. 
3.1.3 LAA-specific CD4+ T-cells (Groupleaders: Buhmann, Milosevic, Kolb, 
Schmetzer; scientists: Steger) 
CD8+ T-cells recognize HLA-class I restricted peptides, therefore they can mediate strong 
cytotoxic, antileukemic reactions, but also severe graft versus host (GvH) disease. In contrast 
CD4+ T-cells recognize HLA class II restricted peptides that are mainly expressed by cells of 
the haematopoetic system and absent from other organs. In order to further analyse the 
antileukemic function of CD4+ T-cells we prepared (untouched) CD4+ T-cells from 6 
patients, as given in table 3.1.3-1, after SCT or DLI immunotherapies and stimulated them 
with LAA-proteins (WT1, PRAME, PR1 and the mHA HA-1), that were loaded on the CD4 
depleted cell fraction (containing monocytes and DC as antigen presenting cells (APCs)) or 
on ‘mini-LCL’. 
During the stimulation phase the cells lost their naïve (and central memory) T-cell 
phenotype and gained an effector memory or effector cell phenotype (data not shown). 
As already shown for CD8 selected T-cells cytokine release assays for IFN-Ǆ (ELISPOT, ICS) 
or GM-CSF (ELISA) did not reveal  clear and specific cytokine release profiles of LAA or 
HA-1 stimulated, expanded or cloned CD4+ T-cells (data not shown).  
Therefore we performed  a functional Fluorolysis assay in case pt 1158: blast cells of the 
patient, that were characterized by a overexpression of WT1, PRAME and PR1 at first 
diagnosis served as leukemic target and  fibroblasts, effector cells or non-blast cells of the 
patient as negative controls. Effector cells (E) used for these assays were: unstimulated  MNC, 
CD3+ or CD4+ T-cells obtained in different stages of the disease, LAA or HA-1 stimulated 
CD4+ T-cells in different stimulation phases, enriched proliferating and CD40L+ CD4+ cells 
before or after single cell cloning (table 3.1.3-2).  
We could demonstrate that most of the CD4+ T- cell containing effector cell fractions (except 
MNCs before SCT, CD4+ T-cells after 16 stimulation rounds (E11) and two of the CD4+ T-
cell clones (E13, E15)) were able to regularly and specifically lyse leukemic blasts, but not 
fibroblasts or non-blast-cells of the patient. Highest antileukemic activity was demonstrated 
for enriched proliferating and CD40L+CD4+ T-cells followed by one of the three tested 
clones. Unfortunately despite of provable (CD4+) immunity against leukemic cells the 
patient died two years after SCT in hematological CR from a myocardial chloroma. 
www.intechopen.com
 
The T-Cells’ Role in Antileukemic Reactions - Perspectives for Future Therapies’ 
 
69 
Patients (pt) Dgn. 
T-cell source  
(stage of 
disease) 
Blasts in 
PB at 
sample 
aquisition
Cell source 
Analyses performed 
 in addition 
 to CD4+experiments 
pt 1153 
MDS-
CMML 
Pers after SCT 8 
CD4+,  CD8+, 
MNCs 
ICS, IFN-Ǆ  ELISPOT, 
MHC-Multimer  
staining, LAA analyses  
pt 1154 
MDS-
RAEB II
CR after SCT 0 
CD4+,  CD8+, 
MNCs
ICS, IFN-Ǆ  ELISPOT, 
LAA analyses 
pt 1155a and 1155 b 
MPS-
atyp. 
CML
CR after SCT 0 
CD4+,  CD8+, 
MNCs 
ICS, IFN-Ǆ  ELISPOT,  
GM-CSF ELISA, LAA 
analyses 
pt 1156 
Biphen. 
ALLL/ 
AML
CR after SCT 0 CD4+ IFN-Ǆ  ELISPOT 
pt 1157 AML-M4 CR after SCT 0 CD4+ IFN-Ǆ  ELISPOT 
pt 1158 a (‘E1’) 
AML-
M4
CR before SCT 0 MNCs 
LAA analyses, 
Fluorolysis assay 
pt 1158 b (‘E2’) 
AML-
M4 
CR after 1st
SCT and 1st 
DLI
0 CD4+  Fluorolysis assay 
pt 1158 c (‘E3’) 
pt 1158 d (‘E12’: after P5) 
pt 1158 e (’E11’: after P16) 
pt 1158 f (‘E6’: after P17,FACS-
Sort,  P14) 
pt 1158 g, h, i (‘E13, 14, 15’ clones, 
after FACS-Sort,  P14)
AML-
M4 
CR after 1st 
SCT and 1st 
DLI 
0 CD4+ 
ICS, IFN-Ǆ  ELISPOT, 
GM-CSF ELISA , 
Fluorolysis assay 
pt 1158 p (‘blast targets’) 
AML-
M4
Rel. after 1st SCT 
and  2nd DLI
34 
CD3 depleted 
blasts
 Fluorolysis assay 
pt 1158 j (‘E4’) 
AML-
M4
Rel. after 1st SCT 
and 2nd DLI
nd CD4+ Fluorolysis assay 
pt 1158 k (‘E5’) 
AML-
M4
CR after 2nd SCT 
and 4th DLI
0 CD4+ Fluorolysis assay 
pt 1158 l (‘E16’) 
AML-
M4
CR after 2nd SCT 
and 4th DLI
0 CD4+ Fluorolysis assay 
pt 1158 m, n, o (‘E7, 8, 9’) 
AML-
M4
CR after 2nd SCT 
and 4th DLI
0 
MNCs, CD3+, 
CD4+
LAA analyses, 
Fluorolysis assay 
Dgn. diagnosis; Pers persistant disease; Rel. relapse;  CR complete remission; MDS myelodysplastic 
syndrome; RAEB Refractory Anaemia with Excess Blasts; AML-M3 acute myeloid leukemia FAB M3; 
CMML Chronic Myelomonocytic Leukemia; LAA leukemia associated antigen, overexpression 
analyses compared to healthy controls, detected by the RQ= 2-ΔΔct method in MNCs; E effector cells 
prepared at different time points in the course of the disease or after stimulation with CD4 depleted 
LAA/HA1 protein loaded APCs; P passage after x stimulations with CD4 depleted LAA/HA1 
protein loaded APCs, nd not done; 
Table 3.1.3-1 Patients´ characteristics II:  
A flow chart with the methodological strategy to create LAA-presenting nonCD4+ cells or 
mini-LCL is given in figure 3.1.3-1. We could demonstrate that in general it is possible to 
stimulate untouched CD4+ T-cells using the CD4 depleted fraction or ‘mini-LCL’ as 
stimulator fraction. Furthermore we enriched LAA-stimulated cells from these stimulation 
settings by either enrichment of proliferating, CD40L+CD4+ T-cells or by T-cell single-cell 
cloning after repeated stimulation with LAA- and HA-1-  loaded stimulator cells. Resulting 
cells were characterized by proliferation, CD40L upregulation and cellular expansion.  
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blood
Ficoll separation
MACS separation  
(untouched CD4+)
nonCD4+ cells
mini-LCLs 
(EBV tranformed B-cells)
FACS control
(purity of CD4+, composition of nonCD4+)
LAA/HA1 protein loading
CD4+ T-cells
LAA/HA1 presenting 
mini-LCL
LAA/HA1 presenting 
nonCD4+ cells
stimulation with irradiated LAA/HA1 loaded 
nonCD4+ cells/mini-LCLs
(43/80 Gy)
 
I. Untouched CD4+ T-cells prepared from AML patients’ PBMNC after SCT were stimulated (6-16 
stimulations with 20 U IL2 twice a month) with irradiated (43 Gy, 80 Gy by mini-LCLs), LAA/HA1 
protein loaded nonCD4 cells (as APCs) for 24h. Alternative stimulation of the nonCD4+ cell fraction 
with EBV transformed B-cells as APCs. 
 
CD4+ T-cells,
IL2 stimulated
(after 6-16 LAA/HA1
stimulations)
IFN-Ǆ ELISPOT/ICS,
GM-CSF ELISA
(pt: 1158, 1155b*, 1157)
IFN-Ǆ ELISPOT
(pt: 1153, 1154, 1155a, 
1156)
IFN-Ǆ ELISPOT
IFN-Ǆ ELISPOT,
GM-CSF ELISA,
51 Cr assay,
Fluorolysis assay,  
FACS
FACS cell sorting
(CD4+, CD154+, CFSE low,
pt: 1158, 1155b*)
single cell 
cloning
(pt: 1158, 1155b*)
single cell 
cloning
(pt: 1156)
* mini-LCLs stimulated;
 51 Cr  Chromium-release assay  
II. Stimulated CD4+ T-cells were characterized by ELISPOTS, ELISAS or ICS for secretion of IFN-Ǆ or 
GM-CSF before or after single cell cloning or sorting of CD40L+ CFSElow cells. Moreover some cases 
were tested for antileukemic activity in a chromium-release or fluorolysis assay. 
Fig. 3.1.3-1. Preparation, stimulation (I) and characterisation (II) of (untouched) CD4+T-cell  
I. 
II. 
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Patient 
1158 
T-cell source 
(stage of 
disease) 
Cell source
of 
the effectors
Proportion 
of blasts 
lysed by 
different 
effector 
cells (%) 
Patient
T-cell source 
(stage of 
disease) 
Cell source 
of 
the effectors 
Proportion 
of blasts 
lysed by 
different 
effector 
cells (%) 
 
pt 1158 a 
(‘E1’) 
 
CR before 
SCT 
MNCs 0 
 
pt 1158 f 
(‘E6’) 
 
CR after 1st 
SCT and 3 
weeks after 1st
DLI 
CD4+ 
(after P17 
and FACS 
Sort P14) 
87 
 
pt 1158 b 
(‘E2’) 
 
CR after 1st 
SCT and 3 
weeks after 
1st DLI 
CD4+ 51 
 
pt 1158 e 
(‘E11’) 
 
CR after 1st 
SCT and 3 
weeks after 1st
DLI 
 
CD4+ 
(after P16) 
0 
pt 1158 c 
(‘E3’) 
CR after 1st 
SCT and 5 
weeks after 
1st DLI 
CD4+ 42 
 
pt 1158 d 
(‘E12’) 
 
CD4+ 
(after P5) 
9 
pt 1158 j 
(‘E4’) 
Rel. after 1st 
SCT and 2nd 
DLI 
CD4+ 61 
pt 1158 g 
(‘E13’) 
CD4+  T-cell 
clones 
(after FACS 
Sort P14) 
0 
pt 1158 k 
(‘E5’) 
CR after 2nd 
SCT and 4th 
DLI 
CD4+ 60 
pt 1158 h 
(‘E14’) 
16 
 
pt 1158 
m (‘E7’) 
 
CR after 2nd 
SCT and 4th 
DLI 
MNCs 22 
pt 1158 i 
(‘E15’) 
0 
 
pt 1158 n 
(‘E8’) 
 
CD3+ 
19 
(38, 4h) 
pt 1158 l 
(‘E16’) 
CR after 2nd 
SCT and 4th 
DLI 
CD4+ 86 
 
pt 1158 o 
(‘E9’) 
 
CD4+ 9 pt 1158 q  Myocardial Chloroma 
E effector cells prepared at different time points in the course of the disease or after stimulation with 
CD4 depleted LAA/HA1 protein loaded APCs (table 3.1.3-1); P passage after x stimulations with CD4 
depleted LAA/HA1 protein loaded APCs;  Exitus letalis 
Table 3.1.3-2 Antileukemic functionality (demonstrated by fluorolysis assay) of different 
CD4+ effector cells prepared before or after specific stimulation, enrichment or sorting  
In summary this means that the cytokine release of IFN-Ǆ or GM-CSF is no reliable tool to 
detect specificity in T-cell fractions. We could demonstrate however, that CD4+ T-cells in 
general can mediate cytotoxic reactions and that certain enriched CD4+ subtypes might be 
even more promising candidates for GvL- without GvH reactions.  
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3.2 T-cells addressing unknown leukemia-specific antigens 
3.2.1 Establishment and maintenance of protective immunity by dendritic cells 
derived from leukemic blasts (Groupleaders: Borkhardt, Buhmann, Schmetzer; 
Scientists: Fischbacher, Freudenreich, Grabrucker, Liepert, Merle, Reuther, Schick, 
Schuster, Vogt) 
Although technically possible the preparation of LAA-specific T-cells is cumbersome, in case 
of MHC-Multimer technology HLA-A2 restricted and moreover restricted to defined LAAs. 
Therefore we wanted to study the antileukemic activity of T-cells stimulated with DC 
derived from leukemic blasts (DCleu), as those DC bear the advantage of potentially 
presenting the whole (including as yet unknown) and patient-typical antigen pool of the 
leukemic cells. We have already established the methods to generate sufficient amounts of 
DC and especially of DCleu in every given case with AML: in a minimalized assay we 
cultured DC in three different media and choose the DC generation method with the 
quantitatively highest DC/DCleu counts (Kremser et al., 2010;  Schmetzer et al., 2007). In a 
next step we study the functional profiles of DC/DCleu-stimulated T-cells. We could 
demonstrate, that isolated unstimulated T-cells were able to lyse blasts in 47% of cases, 
whereas only 26% of those T-cells showed antileukemic activity after a 10 days culture with 
blasts – pointing to an establishment of a T-cell inhibitory microenvironment in the presence 
of blasts. However, stimulation of T-cells with blasts after their conversion to DCleu resulted 
in a blast lytic activity in 58% of all cases. These data suggest, that the inhibitory (blast-
induced) atmosphere could be abolished after blast-conversion to DCleu, although not 
completely: even a DC/DCleu stimulation of T-cells was not effective to induce antileukemic 
T-cells in every case (Schmetzer  et al., 2011; Grabrucker et al., 2010). Therefore we analysed 
potential conditions and factors being responsible for these impaired immune reactions. We 
could demonstrate that the quality of DC – especially with respect to proportions of mature 
DC and DCleu – is predictive for their activation capacity for antileukemic T-cells. Those 
DC/DCleu induce an ‚antileukemically effective’ T-cell composition of DC-stimulated T-cells, 
characterized by higher proportions of CD4+ and non-naive T-cells (Grabrucker et al., 2010; 
Liepert  et al., 2010). A detailed analysis of T-cells’ compositions in cases with compared to 
those without antileukemic activity revealed significantly higher proportions of naïve (Tnaive)  
and central memory T-cells (Tcm) and lower proportions of effector memory regulatory 
(Teff/em reg) as well as CD8+ regulatory T-cells (CD8+ Treg) (Schick et al., 2011; Vogt et al., 
2011). Moreover we could define soluble factors that are predictive for the mediation of 
antileukemic activity of DC/DCleu-stimulated T-cells: A higher release of ‘inflammatory’ 
chemokines (CXCL8, CCL2) in DC culture supernatants or of ‘T-cell-promoting’ cytokines 
(IFN-Ǆ, IL-6) in mixed lymphocyte culture (MLC) supernatants of T-cells with DC clearly 
correlated with antileukemic activity of DC-stimulated T-cells (Fischbacher et al., 2011; 
Merle et al., 2011; Schmetzer  et al., 2011).  
Detailed studies of T-cell subsets via spectratyping analysis could verify that especially after 
DC-stimulation CD4+ as well as CD8+ T-cells were characterized by a highly restricted Vß 
T-cell-receptor (TCR) repertoire (Schuster et al., 2008). Interestingly, in one patient studied 
comprehensively in vitro stimulation with DC/DCleu resulted into an identical TCR  chain 
restriction pattern which could be identified in vivo in the patient’s T-cells 3 months after 
allo-SCT (Reuther et al., 2011). 
In summary, DCleu are promising candidates to stimulate and enrich antileukemic T-cells 
without knowledge of defined antigen targets which is attended with the creation of an 
‘antileukemic cellular microenvironment’ and could contribute to develop strategies to 
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overcome immunological resistances. With our experimental in vitro models combining 
culture methods and functional flow cytometry with spectratyping we can moreover 
provide explanations for clinical observations and might provide predictive information 
about T-cellular response patterns in vivo. Further studies of selected T-cells (e.g. by their Vß 
type) for their phenotype and function will allow to understand clinical responses and to 
prepare T-cells for treatment. 
3.2.2 Antileukemic T-cell profiles to predict antileukemic reactions of DC/DCleu 
stimulated T-cells and prognosis of patients (Groupleaders: Schmetzer; Scientists: 
Fischbacher, Freudenreich, Grabrucker, Liepert, Merle, Schick, Vogt) 
Since not every AML patient responds to immunotherapy (SCT, DLI) in vivo and since not 
every ex vivo T-cell stimulation with DCleu results in antileukemia effector T-cells we wanted 
to elucidate responsible cells or soluble factors. We could evaluate ‘cut-off values’ for DC- or 
T-cell subtypes in the cellular settings and in addition amounts of soluble factors that allow 
a prediction of the antileukemic function of T-cells in this cellular or microenvironmental context 
or a prediction of the clinical response to immunotherapy. We could demonstrate, that T-cells 
stimulated with DCleu in a ‘favorable cellular and soluble chemokine/cytokine context’ 
(with >45% mature DC and >65% DCleu with a release of >200pg CXCL8, >100pg CCL2, 
>10pg IFN-Ǆ  or >15pg  IL-6, resulting in >65% CD4+, Tnon-naive and <60% CD8+ T-cells and 
especially >3% Tnaive  , >11% Tcm and  low proportions of CD8+ Treg after the DC stimulation) 
had a more than 75% chance to gain antileukemic ex vivo activity. In addition we could 
demonstrate, that clinical responders to  immunotherapy were characterized by a higher ex 
vivo generability of DCleu and mature DC, a better ex vivo T-cell proliferation and CD4:CD8 
and Tnon-naive : Tnaive ratios>1 and in addition by a high release of CCL2, IFN-Ǆ  and IL-6 
(Liepert et al., 2010; Schmetzer et al., 2011; Fischbacher et al., 2011; Merle et al., 2011; 
Grabrucker et al., 2010).  
That means, that we can not only associate cellular subtypes of T-cells and DC or 
cytokine/chemokine release patterns with antileukemic functions of T-cells in ex vivo 
settings and in the context of a clinical response to immunotherapies, but in addition define 
predictive ‘cut-off values’ , that means proportions of cells with certain cellular subtypes or 
concentrations of soluble factors, that allow a correlation with cellular responses or the 
clinical course of the disease after immunotherapy. 
4. Clinical key results 
4.1 Clinical use of donor T-cells for prevention and treatment of AML relapse after 
allogeneic SCT ( Schmetzer, Schmid) 
Donor lymphocyte infusion (DLI) for treatment of leukemic relapse after allogeneic 
hematopoietic stem cell transplantation (SCT) has been introduced in the early nineties 
(Kolb et al., 1990). Being extremely effective in chronic myeloid leukemia, the procedure was 
less successful in AML, although remissions were observed in selected cases (Kolb et al., 
1995; Collins et al., 1997). Therefore, on behalf of the Acute leukemia Working Party of the 
European Group of Blood and Marrow Transplantation (EBMT) our group performed a 
retrospective analysis of patients who had been transplanted for AML in complete 
remission, and had suffered from leukemia relapse post SCT (Schmid et al., 2007). The 
analysis was based on the EBMT transplant registry, and included 399 adult patients who 
had received (n=171) or not (n=228) DLI as part of their treatment. With a median follow up 
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of 27 and 40 months in the both groups, overall survival (OS) at two years was 21±3% for 
patients receiving, and 9±2% for patients not receiving DLI. After adjustment for differences 
between the groups, better outcome was associated with younger age (p= 0.008), remission 
duration >5 months after SCT (p<0.0001), and use of DLI (p=0.04). Among DLI recipients, a 
lower tumour burden at relapse (<35% of bone marrow blasts; p=0.006), female gender 
(p=0.02), favorable cytogenetics (p=0.004) and remission at time of DLI (p<0.0001) were 
predictive for survival in a multivariate analysis. Two-year survival was 5610%, if DLI was 
performed in remission or with favourable karyotype, and 153% if DLI was given in 
aplasia or with active disease. Therefore, an algorithm for the clinical use of DLI in the 
treatment of relapsed AML after allogeneic SCT was developed, comprising the sequence of 
cytoreductive chemotherapy for disease control or induction of complete remission, 
followed by DLI for long term control of the leukemia based on cellular immune effects  
(Schmid et al., 2011).  
In an approach to increase the antileukemic efficacy of donor T-cells against myeloid 
leukemias, systemic application of GM-CSF was studied after DLI for relapse of AML or 
MDS after SCT (Schmid et al., 2004). GM-CSF was chosen due to its capacity to contribute in 
vitro to the generation of antigen-presenting cells (APC) from leukemic blasts 
(Woiciechowsky et al., 2001; Kufner  et al., 2005;  Kremser et al., 2010; Dreyssig et al., 2011). 
As described above, blasts from myeloid leukemias should have the full genetic repertoire 
for effective antigen presentation, but might be ineffective stimulators or even induce 
specific anergy, due to inferior or aberrant expression of co-stimulatory molecules, such as 
CD80 or CD86. GM-CSF has been shown to induce up-regulation of these molecules on 
the surface of leukemia blasts and to improve cytotoxic efficacy of autologous and 
allogeneic T-cells. In a clinical pilot trial for AML relapse after SCT, mild chemotherapy 
with low dose AraC, infusion of donor T-cells together with stem cells for reconstitution 
of haematopoiesis, and s.c. or i.v. application of GM-CSF, was studied. Overall response 
rate was 67% among evaluable patients’, overall survival at 2 years was 29%. Long term 
survival was associated with longer remission post transplant, disease control by low 
dose AraC and development of chronic GvHD. These results confirm the proposed 
strategy of initial cytoreduction by chemotherapy and induction of a GvL reaction for 
long term disease control. Systemic application of GM-CSF was safe in this setting, 
however, its clinical efficacy remains to be evaluated in randomised studies. Nevertheless, 
in accompanying ex vivo experiments we could demonstrate, that cases in which DC could 
be generated ex vivo using GM-CSF-based protocols showed a more favourable outcome 
after in vivo immunotherapy (Freudenreich et al., 2011).  
Since overall, the outcome of patients with AML who relapse after allogeneic SCT is poor, 
strategies to prevent occurrence of overt haematological relapse are of increasing interest. 
Intensive monitoring of minimal residual disease and donor chimerism in different cellular 
compartments (CD34+, CD3+) of bone marrow or peripherial blood has gained in 
importance by allowing early interventions (chemotherapy, DLI, second SCT) before 
haematological relapse has occurred (Bornhauser et al., 2009). Our group has developed a 
protocol for the use of prophylactic or preemptive DLI (pDLI) for patients with high-risk 
AML. Starting from day +120 after SCT, patients in haematologic remission, free of 
immunosuppression for at least 30 days without clinically evident GvHD, and free of 
infections receive up to 3 courses of DLI in 4 weeks’ intervals,  using an escalating cell dose 
schedule. Patients receiving prophylactic DLI have been compared to a control group of 
high-risk AML patients, who were treated according to the same transplant protocol,  would 
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have fulfilled the criteria for pDLI, but did not receive the cells since their transplant centres 
did not take part at this part of the study (Schmid et al.,  2005; Schleuning et al., unpublished 
results). Hence, patients receiving pDLI showed a significantly lower incidence of relapse 
and achieved a longer overall survival as compared to controls without pDLI. The treatment 
was also safe and induction of severe GvHD was a rare event in this setting.   
In summary, although less effective as in CML, the clinical use of DLI for AML patients after 
SCT is an effective therapeutic tool for prevention or as part of treatment of relapses after 
SCT in AML. 
5. Perspectives for future therapies: Adoptive transfer or in vivo activation of 
antileukemic T-cells? (Schmetzer, Schmid) 
We could clearly demonstrate, that it is possible to detect and monitor leukemia specific T-
cells by  LAA-peptid specific (HLA-A2 restricted) MHC-Multimer analyses or LAA-protein 
specific CD4+ T-cells, especially if combined with spectratyping and cellular subtype 
analyses. Concerning ‘known’ (leukemia-) specific antigens we can conclude from our data, 
that LAA-peptide specific CD8+ T-cells can be prepared by MHC multimer-technology,  
LAA-protein specific CD4+ T-cells  by preparation of (enriched) proliferating CD40L+ or 
cloned CD4+ cells and both cell types could be used for adoptive therapies. Moreover we 
could work out in vitro as well as in a dog model, that male specific antigens might be 
promising candidate antigens for immunotherapies. In addition we could show, that 
(enriched) T-cells addressing known as well as unknown leukemia-associated antigens, as 
demonstrated after DC/DCleu-stimulation, can mediate cytotoxic reactions. Those cells 
could be promising candidates for adoptive immunotherapies in selected patients. 
Since the manipulation and selection of antigen-specific T-cells is not only an oncological 
challenge, but has to be approved by special committees before a clinical application another 
strategy circumventing T-cell manipulations could be more promising: applicating immune-
modulators  and cytokines like GM-CSF or IFN-ǂ in vivo could possibly induce the 
conversion of (residual) blasts in patients to DCleu. In a small patients’ cohort we could 
already show, that patients receiving GM-CSF in the context of a DLI-relapse therapy had a 
better chance to respond to this relapse therapy compared to patients without additionally 
applicated GM-CSF (Freudenreich et al., 2011). Moreover we could show, that the 
convertibility of blasts to DCleu in ex vivo settings correlated with the clinical response and 
outcome to immunotherapies, what can be interpretated by an ‘ex vivo simulation’ of the 
DC-generating potential out of blasts. We could even demonstrate, that cases, in that higher 
proportions of DCleu could be generated ex vivo had a longer overall survival compared to 
cases with lower DCleu proportions.  
Our ex vivo focus in the future will therefore be to thoroughly investigate and optimize in 
vivo strategies with allo SCT applying different donor transplants or ex vivo ‘manipulated’ 
grafts. We further want to develop and test different ‘immune modulating cocktails’ 
(Ansprenger et al., 2011; Deen et al., 2011) that can be applicated to patients with the aim 
to induce leukemia-derived DC in vivo and in consequence to stimulate the generation of 
leukemia-specific T-cells in vivo. In parallel we want  to further enlighten the role of 
different (enriched, selected) effector cells – e.g. CD4+, CD8+, NK, NK-T- cells) in the 
mediation of antileukemic reactions in order to find promising candidates for adoptive T-
cell transfer. 
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